drugset / Trial / NCT02322216

Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese Subjects

NCT02322216

Phase 3 Completed 383 enrolled Alcon Research
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to evaluate olopatadine 0.2% QD (once per day) compared to olopatadine 0.1% BID (twice per day) in the treatment of ocular itching associated with allergic conjunctivitis.

Timeline

Start
2014-12
Primary completion
2015-10
Completion
2015-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Olopatadine Other / unclassified 0.1 % Other
Subject Olopatadine Other / unclassified 0.2 % Other

Indications